thesi review deal stock
deal
remain posit given expect continu ep beat
driven acquir store improv front-end margin capit
deploy stock trough-level valuat recogn
stock like behav like deal stock overhang limit nt
upsid investor await management respons pend deal
space believ fundament eventu drive stock higher lt
continu deliv matter last week report above-
consensu ep ebit driven better-than-expect pharmaci ss/top line
time commentari tax wage tax benefit guidanc rose
management rais wage address investor concern wage-
driven margin pressur earn risk valid stabil
fundament seem matter nt lack posit reaction
earn tax guidanc rais disappoint yet also indic broader
overhang stock concern rx price opioid regul risk weigh
rx suppli chain pend landscape-chang hc merger left
investor wait strateg move given reaction seen stock
involv pend deal anticip regulatori scrutini transact see
actual commend disciplin focu though recogn investor
would need get comfort compani lt abil thrive independ
player hc ecosystem pend deal complet
maintain buy nonetheless expect continu
fundamentally-driven ep upsid eventu reward expect
sustain strong ep track record particularli realiz benefit
acquisit store expect front-end ss remain pressur
due reduc discount squar footag move translat
margin gain lastli quantif plan wage bump de-risk
earn key investor concern
buy also driven valuat price-to-earnings trade trough recession-
level multipl alway valu use pe/g vs reduc pt
though note growth assumpt chang risk headlin
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
expect pursu narrow network
commerci part-d drive averag
industri revenu earn growth
wba current geograph exposur prime
materi manag increas store
foot traffic prefer partnership
lt accret exclud potenti store
turnaround adequ bake current stock
abl continu drive averag
industri revenu earn growth via prefer
commerci part-d partnership
beauti differenti redesign privat label focu
translat front-end gross margin expans
ep accret synergi could yield ep
upsid
discount ntm pe/g pt
abl secur place central prefer
beauti differenti redesign privat label focu lift
gross margin higher expect boost front-end
compstore posit territori
synergi exceed guidanc achiev
sooner expect
histor five-year multipl pt
abl win new prefer retail pharmaci
contract lose prefer part-d anchor pharmaci
posit competitor
beauti differenti redesign privat label focu isnt
abl produc higher front-end gross margin compstore
realiz synergi lower expect store
turnaround process take longer expect
page
pleas see import disclosur inform page report
investor expect good
result anticip increas
wage rate also expect
mostli wipe wba estim tax
save view mgmt net
increas tax save project
posit surpris
reflect stock post-releas
loss
expect deceler
same-stor trend year due
anniversari prime tricar
win expect sustain
translat mid-single-
digit ebit growth double-digit
though nt trade driven deal dynam
disappoint neg reaction share compani good
earn result posit guidanc adjust head last week
earn releas investor expect good quarter focu
manag would guidanc given expect tax benefit
anticip wage increas necessari keep salari paid
retail feedback investor call head quarter
expect wage gain mostli off-set tax save roll-off certain
part script aet like provid headwind pharmaci same-stor growth
walgreen report ebit beat even greater ep beat driven
better-than-expect revenu trend thought quarter enough underscor
wba good organ revenu growth outlook improv fundament
illustr exhibit consist deliv healthi pharmaci same-stor
revenu growth rang look ahead believ
compani sustain same-stor revenu growth trend combin
emerg oper leverag improv front-end margin albeit expens
front-end same-stor perform squar footag contribut
store acquir last month benefit come closur
under-perform store transfer custom list store oper
enhanc within acquir locat believ arent bake street
expect translat mid-single-digit ebit growth double-digit ep
growth next year note same-stor revenu expect deceler
year though still posit result aet part script roll-off
anniversari prime tricar win
bump wba tax benefit guidanc also posit surpris especi
given investor concern reactionari wage growth would wipe wba benefit
recent tax reform law manag outlin expect increas salari
expens wba net tax gain project still rose
would argu much better expect
given two posit data point typic would suffici drive
share higher especi backdrop weak sentiment expect effect
guidanc cut evid view trade stock least near-term driven less
earn fundament macro factor rx suppli chain sentiment deal market
stories/concern lt strategi given activ space
page
pleas see import disclosur inform page report
recogn nt upsid limit act like deal stock
light two pend mega merger announc last four
month involv two key player pharma suppli chain cvs-aet ci-esrx
understand investor anticip make similar strateg move
compani unlev balanc sheet along mgmt decis refresh
share repurchas author provid increment fuel heighten deal specul
said applaud manag take method surgic approach
exercis patienc pursu deal work strateg neg
stock reaction seen four compani involv pend healthcar
merger highlight risk associ landscape-chang transact
includ expect long-drawn regulatori review detach trade
name respect compani fundament earn trend
believ group bucket near-term especi investor think
wba strateg posit competit decid stay independ
pend deal eventu approv believ stock revert
trade merit time view releas guidanc later year
like catalyst stock trade appropri fundamentally-driven
buy rate also driven valuat trade trough recession-
understand wba growth expect temper high seen
sever year ago acknowledg variou concern rx price opioid regul
risk serv overhang rx suppli chain point
trade near trough price-to-earnings multipl ntm price-to-earnings
recess would argu return trough valuat unwarr wba
growth profil better today
valu share alway look multipl rel
either absolut p/e pe/g ratio given view characterist market cap
growth cash flow match typic compon illustr exhibit
wba valuat delta vs price-to-earnings turn
averag highlight stock highli discount valuat
pull back recent week pressur share view even sever
stock deserv especi given compani continu deliveri posit
earn result miss ep sinc may quarter
page
pleas see import disclosur inform page report
